Lexaria Bioscience (LEXX) News Today $2.23 +0.02 (+0.90%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Lexaria Bioscience forms Scientific Advisory BoardDecember 18 at 9:43 PM | markets.businessinsider.comLexaria Bioscience Corp. (NASDAQ:LEXX) CEO Acquires $51,134.72 in StockDecember 4, 2024 | insidertrades.comLexaria Bioscience’s Promising Developments and Ethics Board Approval Boost Buy RatingNovember 25, 2024 | markets.businessinsider.comLexaria Bioscience completes dosing for GLP-1 human pilot study #3November 25, 2024 | markets.businessinsider.comALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal StudyNovember 21, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight LossNovember 13, 2024 | finanznachrichten.deLexaria Bioscience provides GLP-1 industry updateNovember 8, 2024 | markets.businessinsider.comTinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 ProgramSeptember 13, 2024 | msn.comLexaria Bioscience (NASDAQ: LEXX) Shares Letter from Outgoing CEOSeptember 10, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) LiraglutideSeptember 8, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Announces Agreement to Evaluate DehydraTECH(TM) in Pre-Clinical SettingSeptember 5, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Announces Additional Tolerability, PK Test ResultsAugust 31, 2024 | theglobeandmail.comHempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test ResultsAugust 29, 2024 | msn.comLexaria Bioscience Corp.: First Results from Lexaria's Second GLP-1 Human Pilot StudyAugust 28, 2024 | finanznachrichten.deLexaria (NASDAQ: LEXX) Announces Positive Interim Animal Study Results on DehydraTECH-CBD in Diabetes ControlAugust 22, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal StudyAugust 21, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Positive Results from Lexaria's Molecular Characterization StudyAugust 19, 2024 | finanznachrichten.deLexaria Bioscience (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Results from Animal StudyAugust 8, 2024 | theglobeandmail.comLexaria’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen HormoneAugust 4, 2024 | msn.comVanessa Carle Sells 2,567 Shares of Lexaria Bioscience Corp. (NASDAQ:LEXX) StockAugust 3, 2024 | insidertrades.comLexaria Bioscience Corp. (NASDAQ:LEXX) Insider Vanessa Carle Sells 2,567 SharesLexaria Bioscience Corp. (NASDAQ:LEXX - Get Free Report) insider Vanessa Carle sold 2,567 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $4.00, for a total transaction of $10,268.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.August 1, 2024 | marketbeat.comInvenomic Capital Management LP Sells 258,716 Shares of Lexaria Bioscience Corp. (NASDAQ:LEXX)Invenomic Capital Management LP cut its stake in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX - Free Report) by 35.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 473,265 shares of the company's stockJuly 31, 2024 | marketbeat.comLexaria (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study DosingJuly 23, 2024 | theglobeandmail.comBuy Rating for Lexaria Bioscience on Promising DehydraTECH Efficacy and Solid FinancialsJuly 19, 2024 | markets.businessinsider.comBuy Rating on Lexaria Bioscience Fueled by Promising DehydraTECH Advances in Diabetes Drug DevelopmentJuly 19, 2024 | markets.businessinsider.comLexaria Bioscience (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, EpilepsyMay 23, 2024 | theglobeandmail.comLexaria Receives Two New Medical-Treatment Patents in Hypertension and EpilepsyMay 21, 2024 | finance.yahoo.comLexaria (NASDAQ: LEXX) Announces Commencement of Dosing in GLP-1 Animal StudyMay 20, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Looking to Tap into Various Growing MarketsMay 17, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Dosing Begins in Lexaria's Comprehensive GLP-1 Animal StudyMay 17, 2024 | finanznachrichten.deLexaria (NASDAQ: LEXX) Set to Extend Runway to 2025 Following Warrant Exercise, IssuanceMay 10, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2May 9, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Targeting Massive Type 2 Diabetes and Obesity Markets with DehydraTECH(TM)May 8, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria Begins Dosing of Its Second GLP-1 Human Pilot StudyMay 8, 2024 | finanznachrichten.deLexaria (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 DrugsMay 7, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and IssuanceApril 30, 2024 | finanznachrichten.deLexaria Bioscience, BioSig Technologies, BIMI Holdings among healthcare moversApril 17, 2024 | msn.comLexaria Bioscience Corp.: Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 StudyApril 16, 2024 | finanznachrichten.deLexaria Bioscience Corp LEXXApril 5, 2024 | morningstar.comLexaria (NASDAQ: LEXX) Marks 2024 Milestone with FDA Clearance for Planned U.S. Phase 1b Hypertension TrialMarch 19, 2024 | theglobeandmail.comLexaria Bioscience Revolutionizes Drug Delivery with DehydraTECH for GLP-1 drugMarch 18, 2024 | proactiveinvestors.comLexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFOMarch 15, 2024 | theglobeandmail.comLexaria Bioscience Corp.: Lexaria Appoints Nelson Cabatuan as Chief Financial OfficerMarch 14, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Awards Contract For Next GLP-1 Human Pilot StudyMarch 7, 2024 | finanznachrichten.deLexaria to test DehydraTECH GLP-1 product for weight loss, diabetesMarch 5, 2024 | msn.comLexaria Bioscience Corp.: 7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal StudyMarch 4, 2024 | finanznachrichten.de7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal StudyMarch 4, 2024 | finance.yahoo.comLexaria slips despite FDA nod to test blood pressure drugMarch 1, 2024 | msn.comThis Lexaria Bioscience Insider Increased Their Holding By 23% Last YearFebruary 18, 2024 | finance.yahoo.comLexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 16, 2024 | finance.yahoo.com Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this coin BEFORE Inauguration Day … (Ad)Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office. This could be his favorite coin. LEXX Media Mentions By Week LEXX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LEXX News Sentiment▼0.000.61▲Average Medical News Sentiment LEXX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LEXX Articles This Week▼11▲LEXX Articles Average Week Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADAP News Today PBYI News Today TIL News Today BDTX News Today GALT News Today ELUT News Today CGEN News Today TELO News Today ENTA News Today MNPR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LEXX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
